Atopic dermatitis: Baricitinib 'shows long-term efficacy'

An extension study shows response to the oral Janus kinase inhibitor can be maintained for 16 months in about half of responders

The rheumatoid-arthritis drug baricitinib reduces symptoms of moderate to severe atopic dermatitis (AD) for at least 68 weeks, according to an extension study of two randomised controlled trials.

atopic dermatitis on the fingers

BREEZE-AD3 is an ongoing, double-blind extension of the earlier phase-3 BREEZE-AD1 and BREEZE-AD2 trials and is taking place at sites across Europe, Asia, Latin America, and Australia.

Patients classified as responders or partial responders in the earlier (16-week)

Latest